TRSSF - These Canadian Cannabis Producers May Benefit From an Israeli Medical Innovation
According to Health Canada, the Canadian medical cannabis market currently contains 320,000 registered patients, and an estimated total of 8 million Canadians experience chronic pain. An Israeli pharma-tech, Syqe Medical, which specializes in inhalation devices for therapeutic drugs, has developed an innovative medial cannabis inhaler -- touted as a first of its kind -- to help treat these patients. During its announcement of regulatory approval in Canada on April 28, the company did not name a licensed producer. However, there is reason to believe that the licensed producer could be a North American cannabis operator headquartered in Canada called TerrAscend (OTC: TRSSF) .
The Syqe Inhaler is devised to provide metered doses of aerosolized cannabinoids to the lungs with minimal patient training. The inhaler allows for self-administered doses effective in relieving pain while strongly limiting unwanted side effects such as psychoactivity, which comes from high levels of tetrahydrocannabinol (THC). The company's clinical trials show that its inhaler usage has homed in on what's called a therapeutic window of 500 micrograms of THC per dose. By comparison, patients who smoke medical cannabis as a treatment are at risk of administering 300 times those levels, which can lead to unnecessary side effects.
Image source: Getty Images.
For further details see:
These Canadian Cannabis Producers May Benefit From an Israeli Medical Innovation